Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
MCF-H82E6 | Human | Biotinylated Human M-CSF / CSF-1 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
MCF-H5247 | Human | Human M-CSF / CSF-1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Biotinylated Human M-CSF, His,Avitag (Cat. No. MCF-H82E6) stimulates proliferation of RAW264.7 cells. The EC50 for this effect is 6.20-7.15 ng/mL (Routinely tested).
Biotinylated Human M-CSF, His,Avitag (Cat. No. MCF-H82E6) immobilized on SA Chip can bind Human M-CSF R, His Tag (Cat. No. CSR-H5228) with an affinity constant of 0.309 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Lacnotuzumab | MCS-110 | Phase 2 Clinical | Novartis Pharma Ag | Giant Cell Tumor of Tendon Sheath; Bone metastases; Synovitis, Pigmented Villonodular; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Giant Cell Tumors; Breast Neoplasms; Prostatic Neoplasms; Endometrial Neoplasms; Melanoma | Details |
PD-360324 | PD-360324; PD-0360324 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Neoplasms; Lupus Erythematosus, Cutaneous; Sarcoidosis, Pulmonary | Details |
This web search service is supported by Google Inc.